Global Tobramycin Eye Drop Market Size, Share & Trends Analysis Report, By Type (Tobramycin and Dexamethasone Ophthalmic Suspension, Tobramycin Ophthalmic Suspension, and Other Tobramycin Combination), By Application (Adults and Children), Forecast (2022-2028)

The global tobramycin eye drop market is anticipated to grow at a CAGR of nearly 4.5% during the forecast period (2022-2028). Tobramycin eye drop is prescribed for the prevention of eye related bacterial infections and treating them. In addition to this, tobramycin eye drops are also used for post eye surgery purpose. Tobramycin is usually recommended for use in combination with dexamethasone. These eye drops have also been used in the prevention of ocular infections in certain eye transplant procedures, for instance, penetrating keratoplasty where the eye drop is used for ocular tolerance. The market growth is majorly attributable to the increasing cases of ocular infections during procedures such as penetrating keratoplasty, growing number of clinical studies and the supportive researches focused on analyzing the effectiveness of tobramycin, among others.

Adding to this, the growing prevalence of conjunctivitis also contributes to the growing demand for tobramycin eye drop market. The use of eye drops containing tobramycin has gained popularity among patients suffering from conjunctivitis. Moreover, the growing researches aimed at the clinical efficacy of tobramycin in adult as well as pediatric patients as compared to other eye drops is anticipated to spur the global tobramycin eye drops market. Further, other factors which include increased eye care among individuals, growing diagnostic rates, increasing geriatric population, gradual implementation of enhanced techniques, increased disposable income, and rising healthcare expenditure per capita are also anticipated to support the global tobramycin eye drop market growth during the forecast period.

Some key players operating in the market include Bausch & Lomb, Inc., Novartis International AG, and Akorn Operating Company LLC, among others. The market players are focusing on new product launches, mergers and acquisitions, and partnerships and collaborations. For instance, in March 2020, Eyevance Pharmaceuticals declared the US launch of TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% following the Company’s acquisition of the product in late 2019. TOBRADEX ST (tobramycin/dexamethasone ophthalmic suspension) 0.3%/0.05% is an FDA approved, fixed-dose topical antibiotic and corticosteroid combination indicated for steroid-responsive inflammatory ocular conditions for which a corticosteroid is indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists.

Market Coverage

• The market number available for – 2021-2028
• Base year- 2021
• Forecast period- 2022-2028
• Segment Covered-

• By Type
• By Application

• Regions covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape: Bausch & Lomb, Inc., Novartis International AG, and Akorn Operating Company LLC, among others.

Key questions addressed by the report

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• How COVID-19 impacted the market?

• Deviation from the pre-COVID-19 forecast
• Most affected region and segment
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Tobramycin Eye Drop Market Report by Segment

By Type

• Tobramycin and Dexamethasone Ophthalmic Suspension
• Tobramycin Ophthalmic Suspension
• Other Tobramycin Combination

By Application

• Adults
• Children

Global Tobramycin Eye Drop Market Report by Region

North America

• US
• Canada

Europe

• Germany
• UK
• France
• Spain
• Italy
• Rest of Europe

Asia-Pacific

• China
• Japan
• India
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East and Africa